A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 20
- Registration Number
- NCT06720714
- Locations
- 🇺🇸
UP0141 2, San Antonio, Texas, United States
🇺🇸UP0141 1, Salt Lake City, Utah, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 42
- Registration Number
- NCT06716879
- Locations
- 🇺🇸
UP0142 1, Anaheim, California, United States
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT06668181
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 550
- Registration Number
- NCT06624228
- Locations
- 🇨🇿
Pa0016 40010, Uherske Hradiste, Czechia
🇩🇪Pa0016 40800, Ratingen, Germany
🇭🇺Pa0016 40081, Budapest, Hungary
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 450
- Registration Number
- NCT06617325
- Locations
- 🇺🇸
Sl0044 50550, Chandler, Arizona, United States
🇺🇸Sl0044 50052, Phoenix, Arizona, United States
🇺🇸Sl0044 50670, Searcy, Arkansas, United States
A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 64
- Registration Number
- NCT06555601
- Locations
- 🇧🇪
UP0124 1, Edegem, Belgium
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 12
- Registration Number
- NCT06540144
- Locations
- 🇨🇳
Mg0008 20081, Taipei City, Taiwan
🇮🇹Mg0008 40290, Bologna, Italy
🇵🇱Mg0008 40734, Lodz, Poland
A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 18
- Registration Number
- NCT06533475
- Locations
- 🇩🇪
Up0152 1001, Berlin, Germany
A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 14
- Registration Number
- NCT06511076
- Locations
- 🇳🇱
DV0012 1, Groningen, Netherlands
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT06506916
© Copyright 2024. All Rights Reserved by MedPath